Literature DB >> 16700889

Pharmacogenetics approach to therapeutics.

Seok Hwee Koo1, Edmund Jon Deoon Lee.   

Abstract

1. Pharmacogenetics refers to the study of genetically controlled variations in drug response. Functional variants caused by single nucleotide polymorphisms (SNPs) in genes encoding drug-metabolising enzymes, transporters, ion channels and drug receptors have been known to be associated with interindividual and interethnic variation in drug response. Genetic variations in these genes play a role in influencing the efficacy and toxicity of medications. 2. Rapid, precise and cost-effective high-throughput technological platforms are essential for performing large-scale mutational analysis of genetic markers involved in the aetiology of variable responses to drug therapy. 3. The application of a pharmacogenetics approach to therapeutics in general clinical practice is still far from being achieved today owing to various constraints, such as limited accessibility of technology, inadequate knowledge, ambiguity of the role of variants and ethical concerns. 4. Drug actions are determined by the interplay of several genes encoding different proteins involved in various biochemical pathways. With rapidly emerging SNP discovery technological platforms and widespread knowledge on the role of SNPs in disease susceptibility and variability in drug response, the pharmacogenetics approach to therapeutics is anticipated to take off in the not-too-distant future. This will present profound clinical, economic and social implications for health care.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16700889     DOI: 10.1111/j.1440-1681.2006.04402.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  7 in total

Review 1.  Subtypes of alpha1-adrenoceptors in BPH: future prospects for personalized medicine.

Authors:  Yoshiyuki Kojima; Shoichi Sasaki; Yutaro Hayashi; Gozoh Tsujimoto; Kenjiro Kohri
Journal:  Nat Clin Pract Urol       Date:  2009-01

Review 2.  The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?

Authors:  Mafalda M Dias; Michael J Sorich; Andrew Rowland; Michael D Wiese; Ross A McKinnon
Journal:  Pharm Res       Date:  2017-02-24       Impact factor: 4.200

3.  A whole-genome SNP association study of NCI60 cell line panel indicates a role of Ca2+ signaling in selenium resistance.

Authors:  Sevtap Savas; Laurent Briollais; Irada Ibrahim-zada; Hamdi Jarjanazi; Yun Hee Choi; Mireia Musquera; Neil Fleshner; Vasundara Venkateswaran; Hilmi Ozcelik
Journal:  PLoS One       Date:  2010-09-07       Impact factor: 3.240

4.  Effect of UDP-Glucuronosyltransferase (UGT) 1A Polymorphism (rs8330 and rs10929303) on Glucuronidation Status of Acetaminophen.

Authors:  Huma Mehboob; Imtiaz Mahmood Tahir; Tahira Iqbal; Sadaf Saleem; Sofia Perveen; Aboubakker Farooqi
Journal:  Dose Response       Date:  2017-09-11       Impact factor: 2.658

5.  Association of pro/anti-inflammatory cytokine gene variants in renal transplant patients with allograft outcome and cyclosporine immunosuppressant levels.

Authors:  Parmeet Kaur Manchanda; Anant Kumar; Raj K Sharma; Himanshu Goel; Rama Devi Mittal
Journal:  Biologics       Date:  2008-12

6.  Multiplexed genotyping of ABC transporter polymorphisms with the Bioplex suspension array.

Authors:  Seok Hwee Koo; Tan Ching Ong; Kok Ting Chong; Caroline Guat Lay Lee; Fook Tim Chew; Edmund Jon Deoon Lee
Journal:  Biol Proced Online       Date:  2007-11-01       Impact factor: 3.244

7.  5. Pharmacogenomics and Personalized Medicine.

Authors:  Elizabeta Topić
Journal:  EJIFCC       Date:  2008-04-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.